KR970700771A - 비-바이러스 벡터(Non-viral vector) - Google Patents

비-바이러스 벡터(Non-viral vector)

Info

Publication number
KR970700771A
KR970700771A KR1019960704269A KR19960704269A KR970700771A KR 970700771 A KR970700771 A KR 970700771A KR 1019960704269 A KR1019960704269 A KR 1019960704269A KR 19960704269 A KR19960704269 A KR 19960704269A KR 970700771 A KR970700771 A KR 970700771A
Authority
KR
South Korea
Prior art keywords
viral vector
cell
biotin
administration
human
Prior art date
Application number
KR1019960704269A
Other languages
English (en)
Other versions
KR100376390B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR970700771A publication Critical patent/KR970700771A/ko
Application granted granted Critical
Publication of KR100376390B1 publication Critical patent/KR100376390B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019960704269A 1994-02-07 1995-02-06 면역접합체 KR100376390B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19265594A 1994-02-07 1994-02-07
US08/192,655 1994-02-07

Publications (2)

Publication Number Publication Date
KR970700771A true KR970700771A (ko) 1997-02-12
KR100376390B1 KR100376390B1 (ko) 2003-06-12

Family

ID=22710534

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960704269A KR100376390B1 (ko) 1994-02-07 1995-02-06 면역접합체

Country Status (16)

Country Link
US (1) US6214974B1 (ko)
EP (1) EP0743958B1 (ko)
JP (1) JP4015693B2 (ko)
KR (1) KR100376390B1 (ko)
CN (1) CN1200950C (ko)
AT (1) ATE245662T1 (ko)
AU (1) AU695564B2 (ko)
CA (1) CA2182616A1 (ko)
DE (1) DE69531342D1 (ko)
FI (1) FI963103A (ko)
IL (1) IL112372A (ko)
NO (1) NO319899B1 (ko)
NZ (1) NZ281763A (ko)
RU (1) RU2164943C2 (ko)
SA (1) SA95150519B1 (ko)
WO (1) WO1995021195A1 (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
EP0756213B1 (en) * 1994-02-08 2002-12-04 Research Laboratories of Australia Pty Limited Liquid development type multi-color image formation apparatus
DE19605279A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
AU764603B2 (en) * 1998-07-17 2003-08-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Water-soluble drugs and methods for their production
FR2793414B1 (fr) * 1999-05-10 2003-05-23 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
GB9930533D0 (en) * 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2002100892A1 (en) * 2001-05-29 2002-12-19 Regents Of The University Of Michigan Systems and methods for the analysis of proteins
DE60233509D1 (de) * 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
EP1414471B1 (en) * 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
WO2003082346A1 (fr) * 2002-04-02 2003-10-09 'asgl-Farmatsevticheskie Innovatsii', Zakrytoe Aktsionernoe Obschestvo Proteine chimerique recombinante servant a l'administration ciblee d'adn dans des cellules cibles eucaryotes
AU2003275985A1 (en) * 2002-06-12 2003-12-31 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
DE60305919T2 (de) * 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
CN101104856B (zh) * 2003-11-18 2010-11-10 中国医学科学院基础医学研究所 一个系列的非病毒载体及包含其的药物组合物
RU2393874C2 (ru) * 2005-02-01 2010-07-10 Рисерч Дивелопмент Фаундейшн Полипептиды с направленным действием
TW200730539A (en) * 2005-12-01 2007-08-16 Domantis Ltd Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
US20120171120A1 (en) 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
ES2959258T3 (es) 2013-02-07 2024-02-22 Childrens Medical Center Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
MX2017009272A (es) * 2015-01-16 2018-04-11 Anticuerpos que penetran en células.
CN110730670A (zh) 2017-03-28 2020-01-24 儿童医疗中心有限公司 基于多抗原提呈***(maps)的金黄色葡萄球菌疫苗、免疫原性组合物以及它们的用途
ES2967001T3 (es) 2017-06-23 2024-04-25 Affinivax Inc Composiciones inmunogénicas
BR112021004193A2 (pt) 2018-09-12 2021-05-25 Affinivax, Inc. vacinas pneumocócicas multivalentes
KR20230117327A (ko) 2020-09-03 2023-08-08 어빈 에스.와이. 첸 가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5026785A (en) * 1989-05-12 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Avidin and streptavidin modified water-soluble polymers such as polyacrylamide, and the use thereof in the construction of soluble multivalent macromolecular conjugates
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
ZA932523B (en) * 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP1138334A3 (en) * 1992-06-09 2002-04-03 Neorx Corporation Pretargeting methods and compounds
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
CA2163107C (en) * 1993-05-17 2001-04-17 David Milton Goldenberg Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
EP0733066B1 (en) * 1993-12-07 2003-11-19 NeoRx Corporation Pretargeting methods and compounds

Also Published As

Publication number Publication date
FI963103A0 (fi) 1996-08-06
DE69531342D1 (de) 2003-08-28
NO963283D0 (no) 1996-08-06
ATE245662T1 (de) 2003-08-15
NZ281763A (en) 2001-06-29
KR100376390B1 (ko) 2003-06-12
FI963103A (fi) 1996-10-01
RU2164943C2 (ru) 2001-04-10
NO319899B1 (no) 2005-09-26
SA95150519B1 (ar) 2005-07-24
NO963283L (no) 1996-08-06
AU695564B2 (en) 1998-08-13
EP0743958A1 (en) 1996-11-27
JP4015693B2 (ja) 2007-11-28
AU1868795A (en) 1995-08-21
JPH09508792A (ja) 1997-09-09
EP0743958B1 (en) 2003-07-23
CN1200950C (zh) 2005-05-11
CA2182616A1 (en) 1995-08-10
CN1143374A (zh) 1997-02-19
IL112372A0 (en) 1995-03-30
IL112372A (en) 2001-08-26
EP0743958A4 (en) 1999-07-28
WO1995021195A1 (en) 1995-08-10
US6214974B1 (en) 2001-04-10

Similar Documents

Publication Publication Date Title
KR970700771A (ko) 비-바이러스 벡터(Non-viral vector)
ATE297762T1 (de) Peg-lhrh analog konjugate
ES2194114T3 (es) Formulaciones liposomicas de mitoxantrona.
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
DE69835201D1 (en) Neoglycoproteine
WO1996040757A3 (en) Lhrh antagonist peptides
IL124411A0 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
AU6011496A (en) Improved pharmaceutical compositions for gene therapy
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
EP1003526A4 (en) COVALENT-TIED N, O-CARBOXYMETHYLCHITOSAN AND ITS USE
IL126714A (en) Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
AU5658196A (en) Method for pharmaceutical delivery
MX9806041A (es) Proteina purificada sr-p70.
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
AU1373197A (en) Covalent lipid-phosphonocarboxylic acid conjugates, the production thereof as well as their use as antiviral pharmaceutical agents
DK0934342T3 (da) Præparat indeholdende chitosan
AU5685300A (en) Solid preparations containing paroxetine
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
AU2002218203A1 (en) Transferrin-polycation/dna complexes for the systemic treatment of tumour diseases using cytotoxic proteins
AU8242398A (en) Medicinal compositions for treating immunodeficiency diseases
ZA964925B (en) Pharmaceutical compositions for gene therapy.
MX9708877A (es) P62, sus variantes, las secuencias de acidos nucleicos que los codifican, y su utilizacion en terapia genica anti-cancerosa.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080305

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee